全文获取类型
收费全文 | 2509篇 |
免费 | 202篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 84篇 |
妇产科学 | 42篇 |
基础医学 | 235篇 |
口腔科学 | 49篇 |
临床医学 | 325篇 |
内科学 | 759篇 |
皮肤病学 | 18篇 |
神经病学 | 126篇 |
特种医学 | 271篇 |
外科学 | 269篇 |
综合类 | 29篇 |
预防医学 | 180篇 |
眼科学 | 19篇 |
药学 | 122篇 |
中国医学 | 12篇 |
肿瘤学 | 187篇 |
出版年
2023年 | 15篇 |
2022年 | 9篇 |
2021年 | 40篇 |
2020年 | 31篇 |
2019年 | 34篇 |
2018年 | 50篇 |
2017年 | 33篇 |
2016年 | 50篇 |
2015年 | 50篇 |
2014年 | 62篇 |
2013年 | 92篇 |
2012年 | 97篇 |
2011年 | 83篇 |
2010年 | 86篇 |
2009年 | 104篇 |
2008年 | 95篇 |
2007年 | 81篇 |
2006年 | 105篇 |
2005年 | 86篇 |
2004年 | 84篇 |
2003年 | 83篇 |
2002年 | 80篇 |
2001年 | 78篇 |
2000年 | 74篇 |
1999年 | 74篇 |
1998年 | 69篇 |
1997年 | 75篇 |
1996年 | 78篇 |
1995年 | 63篇 |
1994年 | 55篇 |
1993年 | 58篇 |
1992年 | 53篇 |
1991年 | 30篇 |
1990年 | 40篇 |
1989年 | 61篇 |
1988年 | 68篇 |
1987年 | 60篇 |
1986年 | 50篇 |
1985年 | 43篇 |
1984年 | 29篇 |
1983年 | 31篇 |
1982年 | 32篇 |
1981年 | 22篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1978年 | 11篇 |
1977年 | 19篇 |
1976年 | 16篇 |
1975年 | 19篇 |
1974年 | 8篇 |
排序方式: 共有2733条查询结果,搜索用时 15 毫秒
1.
Carlo De-Carolis Geraldine-A. Boyd Luca Mancinelli Stefano Pagano Stefano Eramo 《Medicina oral, patología oral y cirugía bucal》2015,20(2):e205-e210
With easy chemical synthesis from its precursor, methamphetamine (MA) is now widespread in many countries. The abuse of methamphetamine is associated with several negative effects on health, because MA is a neurotoxin and a dangerous central nervous system stimulant. It changes levels of neurotransmitters in the brain, releasing dopamine and inhibiting nor epinephrine uptake which increases sympathetic nervous system activity and can lead to cardiac arrhythmia, hypertension and tachypnea. The consequences of MA abuse are clearly manifested in oral diseases (like “meth mouth”) which is characterised by extensive caries, teeth grinding with ensuing dental wear and trismus. The present review was designed to fill the gap in knowledge about methamphetamine abuse in the European Union (EU) and to illustrate the main clinical effects of prolonged use. After describing the pharmacology and systemic effects of methamphetamine and concentrating on its effects on the mouth, the present review compares the epidemiology and incidence of abuse in the world, particularly the USA and the EU.
Key words:Methamphetamine, “Meth mouth”, drug abuse, oral health. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
A young patient developed Hodgkin's disease 11 years after surgical, chemotherapeutic and radiation treatment for stage IIIA embryonal carcinoma of the testis. The importance is stressed of establishing a tissue diagnosis when there is an unexpected course of the disease. 相似文献
7.
8.
9.
10.